Compass Pathways/$CMPS

1D1W1MYTD1Y5YMAX

About Compass Pathways

Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Ticker
$CMPS
Sector
Health
Primary listing
NASDAQ
Employees
156
Headquarters
London, United Kingdom
Website
compasspathways.com

Compass Pathways Metrics

BasicAdvanced
$1.9B
-
-$3.61
2.53
-

What the Analysts think about Compass Pathways

Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.

Compass Pathways Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Compass Pathways Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Compass Pathways News

AllArticlesVideos

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

MarketBeat2 weeks ago

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Business Wire3 weeks ago

Compass Pathways Q2 Earnings Call Highlights

MarketBeat3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.